Prognosis of renal cell carcinoma with bone metastases: Experience in 300 consecutive patients.

Authors

null

Fiorella Ruatta

Medical Oncology I, Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo Italy, Candiolo, Italy

Fiorella Ruatta , Lisa Derosa , Laurence Albiges , Christophe Massard , Yohann Loriot , Karim Fizazi , Bernard Escudier

Organizations

Medical Oncology I, Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo Italy, Candiolo, Italy, Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Villejuif, France, Institut Gustave Roussy, Villejuif, France

Research Funding

Other

Background: Bone metastases (BMs) are associated with significant morbidity and shorter survival in metastatic renal cell carcinoma (mRCC). Our purpose was to identify prognostic factors for mRCC patients (pts) with BMs. Methods: Data from mRCC pts with BMs, treated at Gustave Roussy between April 1992 and March 2016, were retrospectively collected. Age, sex, ECOG-Performance Status (PS), Memorial Sloan-Kettering Cancer Center (MSKCC) score, histology, number and site of BMs, concomitant metastases (presence and sites), therapy for BMs (radical resection or palliative surgery, radiotherapy, other local and systemic treatments), time to BMs, and outcome were analyzed. Synchronous solitary bone metastasis (SSBM) was defined as a single bone metastasis without concomitant visceral lesions at the initial diagnosis of RCC. Overall survival (OS) was calculated from the date of BMs diagnosis to death or last follow-up using Kaplan-Maier method and modelled with Cox-regression analysis. Results: Three hundred pts were identified. Median time to BMs was 32.4 months (range 0–324 months). In 64 pts (21%), bone was the only metastatic site and 22 of them (7%) had a SSBM; 236 pts (79%) had concomitant metastases in other sites. Median OS was 23.22 months. SSBM pts had better OS then those with concomitant metastases (40 vs. 20 months; p<0.001). At univariate analysis, number of BMs (p<0.0001), spinal column as site of BMs (p<0.005), concomitant metastases (p<0.0001), Fuhrman grade (p<0.001), non-clear cell histology (p<0.003), and MSKCC score (p<0.001) were significantly associated with poor prognosis. At multivariate analysis, concomitant metastases remained predictor of poor prognosis while good MSKCC, radical resection, and SSBM were predictors of better OS. Conclusions: To our knowledge,this is the largest single-institution experience evaluating prognosis in pts with BMs from RCC. This study suggests that MSKCC score, number of BMs (1 vs. >1) and radical resection are prognostic factors. Additionally, in presence of solitary bone metastasis without other concomitant metastases at the initial diagnosis of RCC, bone surgery should be considered to achieve local tumor control and increase survival.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Track

Renal Cell Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 463)

DOI

10.1200/JCO.2017.35.6_suppl.463

Abstract #

463

Poster Bd #

E2

Abstract Disclosures

Similar Abstracts

First Author: Tingyu WANG

First Author: Margaret Frances Meagher

Abstract

2021 ASCO Annual Meeting

Metastasectomy versus radiation of secondary sites in stage IV breast cancer.

First Author: Nadeem Bilani